Return to homepagePandemic Pact

Delta 4 GmbH

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Austrian Research Promotion Agency (FFG)

  • Principal Investigator

    N/A

  • Research Location

    Austria

  • Lead Research Institution

    Delta 4 GmbH

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Delta4 GmbH will use its big data platform to identify active ingredients that have already been approved for other indications and that have the potential to prevent infection with the novel SARS CoV-2 or to alleviate the severe course of the disease caused by the virus. The most promising drug candidates in computer-aided drug screening are to be examined in in-vitro test series as well as in a clinical study.